Arena Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Arena Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Arena Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Arena Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Arena Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| JP2023548475A | Application | S1p1受容体に関係する病態を治療する方法 | A61K31/4245; A61P29/00; A61P37/02 | November 17, 2023 |
| JP2023548474A | Application | S1p1受容体に関連する状態を処置する方法 | A61K31/403; A61P17/00; A61P29/00; A61P37/02; Y02A50/30 | November 17, 2023 |
| JP2023547893A | Application | 5-ht2aセロトニン受容体に関連する障害を処置するために有用な5-ht2aセロトニン受容体のモジュレーターとしてのイソオキサゾール誘導体 | A61P9/00; C07D261/08; C07D413/12; C07D413/14; C07D417/12; C07D417/14; C07D471/10; C07D487/04; C07D491/107; C07D498/04; C07D498/08 | November 14, 2023 |
| JP2023547892A | Application | 5-ht2aセロトニン受容体に関連する障害を処置するために有用な5-ht2aセロトニン受容体のモジュレーターとしてのピリミジン誘導体 | A61P9/00; C07D239/26; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D405/12; C07D413/12; C07D413/14; C07D417/12; C07D417/14; C07D471/10; C07D487/04; C07D491/08; C07D491/107; C07D498/04; C07D498/08 | November 14, 2023 |
| KR102595163B1 | Grant | S1p1 수용체와 관련된 상태의 치료 방법 | A61K9/4825; A61P29/00; A61P17/06; A61K9/20; A61P37/02; A61P19/02; A61P35/00; A61P17/10; A61P3/10; A61K31/403 | October 30, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer